03 January 2023 : Original article
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and Relapse Settings: A Retrospective Study in China
Jing Liu1BCDEF*, Haitao Wang1BCDF, Xiaohong Li1B, Yamei Wu1B, Yuanyuan Ma1B, Zhenyang Gu1B, Fei Li1B, Meng Li1BD, Jiayuan Guo2B, Yu Zhao1B, Quanshun Wang1B, Jian Bo1B, Wenrong Huang3B, Liping Dou1BD, Yuanbo Liu4AEF, Daihong Liu1BD, Xiaoxiong Wu1ADF, Chunji Gao1ADEFGDOI: 10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
Table 2 ASCT as consolidation treatment for patients newly diagnosed with PCNSL.
| Sex/age | Patient | ECOG | Conditioning regimen | Pre-ASCT | Post-ASCT | Timing of WBRT | N/P engraftment time (days) | Toxicity | ||
|---|---|---|---|---|---|---|---|---|---|---|
| M/45 | 1 | 2 | BEAM | CR | CR | After ASCT | 9/9 | Haematologic toxicities, gastrointestinal toxicities | ||
| M/28 | 2 | 2 | BEAM | CR | CR | – | 11/22 | Haematologic toxicities, fever | ||
| M/61 | 3 | 2 | TBC-like | CR | CR | – | 9/21 | Haematologic toxicities, fever, hepatotoxicity, gastrointestinal toxicities, creatinine increased | ||
| F/48 | 4 | 2 | TBC-like | CR | CR | – | 9/15 | Haematologic toxicities, fever, gastrointestinal toxicities, mucositis | ||
| M/51 | 5 | 3 | TBC-like | CR | CR | – | 8/15 | Haematologic toxicities, hepatotoxicity, fever | ||
| M/33 | 6 | 2 | Modified TBC | CR | CR | – | 10/15 | Haematologic toxicities, gastrointestinal toxicities, infection, mucositis, rash | ||
| F/21 | 7 | 0 | Modified TBC | CR | CR | – | 12/14 | Haematologic toxicities, gastrointestinal toxicities, infection | ||
| M/62 | 8 | 1 | Modified TBC | CR | CR | – | 16/25 | Haematologic toxicities | ||
| F/32 | 9 | 2 | Modified TBC | CR | CR | Before ASCT | 15/25 | Haematologic toxicities, pneumonia | ||
| M/26 | 10 | 0 | Modified TBC | CR | CR | – | 11/31 | Haematologic toxicities, gastrointestinal toxicities | ||
| M/45 | 1 | Epilepsy | Brain | WBRT | CR | 32.0 | 41.2 | DOD | ||
| M/28 | 2 | – | – | – | – | 42.4 | 42.4 | A Wo D | ||
| M/61 | 3 | – | – | – | – | 6.2 | 6.2 | A Wo D | ||
| F/48 | 4 | – | – | – | – | 11.5 | 11.5 | A Wo D | ||
| M/51 | 5 | – | – | – | – | 14.3 | 14.3 | A Wo D | ||
| M/33 | 6 | – | – | – | – | 3.3 | 3.3 | A Wo D | ||
| F/21 | 7 | – | – | – | – | 12.2 | 12.2 | A Wo D | ||
| M/62 | 8 | – | – | – | – | 29.0 | 29.0 | A Wo D | ||
| F/32 | 9 | – | – | – | – | 27.9 | 27.9 | A Wo D | ||
| M/26 | 10 | – | – | – | – | 2.5 | 2.5 | A Wo D | ||
| N/P – neutrophil/platelet; TBC – thiotepa + busulfan + cyclophosphamide; BEAM – carmustine + etoposide + cytarabine + melphalan; Modified TBC – TBC + cladribine + etoposide + cytarabine; CR – complete remission; Cru – unconfirmed CR; HDC – high-dose chemotherapy; PFS – progression-free survival; OS – overall survival; A Wo D – alive without disease; DOD – dead of disease. OS1 and PFS1 were measured from the day of transplantation. | ||||||||||